Intranasal Corticosteroids for Viral Upper Respiratory Infection
Intranasal corticosteroids provide only modest symptomatic benefit in viral upper respiratory infections and are not routinely recommended, but may be considered for symptom relief based on patient preference given their safety profile.
Clinical Context and Evidence
For presumed viral upper respiratory infections (URI), the evidence shows limited benefit from intranasal corticosteroids. A systematic review found that only 73% of patients improved with intranasal steroids compared to 66% with placebo at 14-21 days—a modest 7% absolute benefit 1. This translates to treating 14 patients to achieve one additional symptom resolution 1. The 2015 Adult Sinusitis guideline explicitly states this benefit is "small" and that the decision to use them "should be based largely on patient preference" 1.
Dosing and Duration
When intranasal corticosteroids are used:
- Standard dosing: Use manufacturer-recommended doses for the specific formulation (e.g., mometasone 200 mcg daily, fluticasone 110-220 mcg daily)
- Duration: Continue for the symptomatic period, typically 7-14 days for viral URI 2
- Tapering: Not required for short-term use in acute viral infections
- Onset: Expect symptom relief within 12 hours to several days, slower than antihistamines 3
The 2025 Adult Sinusitis guideline notes that studies using higher doses and 21-day courses showed greater benefit 2, though this applies more to bacterial sinusitis than simple viral URI.
Administration Technique (Critical for Safety)
Patients must direct sprays away from the nasal septum to minimize local adverse effects 3. Examine the nasal septum periodically for mucosal erosions, which may indicate increased risk for septal perforation, though this complication is rare 3.
Contraindications and Precautions
Absolute contraindications:
- Active nasal septal ulceration or recent nasal surgery
- Untreated nasal infections (fungal, bacterial, tuberculous)
Relative contraindications and monitoring:
- Children: Use lowest effective dose with growth monitoring during prolonged therapy 3
- HIV patients on ritonavir: Avoid due to demonstrated adrenal suppression 4
- Existing nasal mucosal erosions: Suggests increased perforation risk 3
Common Adverse Effects
Local effects are most common 2, 1:
- Epistaxis (minor, self-limited)
- Nasal irritation and dryness
- Headache
- Sneezing
Systemic effects are not clinically significant at recommended doses 3, 5. Modern formulations (mometasone, fluticasone propionate/furoate) have minimal systemic bioavailability due to extensive first-pass metabolism 5.
Alternative Therapies (Preferred for Viral URI)
Since intranasal corticosteroids offer only marginal benefit for viral URI, consider these alternatives:
First-Line Symptomatic Options:
- Nasal saline irrigation (isotonic or hypertonic): Low risk, cleansing effect, minor symptom improvement 1
- Analgesics (acetaminophen, ibuprofen): For pain and fever 1
- Oral decongestants (pseudoephedrine): Effective for congestion if no contraindications (hypertension, anxiety) 3, 1
Short-Term Topical Decongestants:
- Oxymetazoline or xylometazoline: Effective but limit to 3-5 days maximum to prevent rhinitis medicamentosa 3, 2, 1
- Some patients develop rebound congestion in as little as 3 days 3
Agents with Questionable/Unproven Efficacy:
- Antihistamines: No clinical studies support use in viral URI (may help if allergic component) 1
- Guaifenesin: Evidence of efficacy lacking 1
- Systemic corticosteroids: No benefit as monotherapy for viral URI; avoid due to immunosuppression risk 2, 6, 7, 8
Clinical Algorithm
For persistent nasal congestion in presumed viral URI:
- First 3-5 days: Nasal saline + analgesics ± short-term topical decongestant
- If symptoms persist beyond 5-7 days: Consider adding intranasal corticosteroid based on patient preference and cost considerations
- If symptoms worsen or persist >10 days with purulence: Reassess for bacterial sinusitis (different treatment paradigm)
Critical Pitfalls to Avoid
- Do not use systemic corticosteroids for viral URI—they provide no benefit and cause immunosuppression 2, 6, 8
- Do not extend topical decongestants beyond 3-5 days—risk of rhinitis medicamentosa 3, 2
- Do not assume purulent discharge means bacterial infection—discoloration reflects neutrophils, not bacteria 2, 1
- Do not prescribe antibiotics for viral URI—symptoms typically peak at 3 days and resolve by 10-14 days 1